What is Triphala?
Triphala is a traditional Ayurvedic herbal formulation consisting of three fruits: Amalaki (Emblica officinalis), Bibhitaki (Terminalia bellirica), and Haritaki (Terminalia chebula). These fruits are dried, powdered, and then blended in specific proportions. It is a cornerstone of Ayurvedic medicine, revered for its balancing effect on the three doshas - Vata, Pitta, and Kapha.
Its preparation involves careful processing to preserve the inherent properties of each fruit, yielding a compound widely utilized for its purported digestive, detoxifying, and rejuvenative benefits.
Other Names of Triphala
- The Three Fruits
- Triphala Churna
Heading
<h3> Absolute Contraindications of Triphala </h3> <h4> Pregnancy and breastfeeding (avoid unless supervised)</h4> <ul> <li>🤰 <li>Recommendation: Do not take Triphala in pregnancy or lactation without a knowledgeable clinician; avoid concentrated or purgative preparations during pregnancy. <li>Reasoning: There are few controlled human pregnancy studies; traditional texts and modern safety reviews advise caution because herbal constituents can alter reproductive biology and no consistent safety data exist for fetal exposure. <li>Scientific_Study_Title: Is it safe to consume traditional medicinal plants during pregnancy? A systematic review and safety guidance. <li>Scientific_Study_Authors: Gurib-Fakim A., et al. (review authors vary - see PubMed entry). <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/33164294/ <li>Scientific_Study_Excerpt: <p>The review summarizes experimental evidence that some medicinal plants produce embryotoxic, teratogenic, or abortifacient effects in animals, and highlights the lack of well-controlled human trials for many traditional remedies. It emphasizes that phytochemicals can cross the placenta, affect uterine contractility or hormone balance, and that safety may depend on dose and gestational timing; as a result, the authors recommend avoiding or using extreme caution with many herbs in pregnancy because preclinical signals cannot be ruled out without human data.</p> </ul> <h4>Acute diarrhea, dysentery or dehydration</h4> <ul> <li>🚱 <li>Recommendation: Do not take Triphala if you currently have watery diarrhea, dysentery, or are dehydrated - it may worsen stool frequency and fluid loss. <li>Reasoning: Triphala has demonstrable laxative/anulomana actions and can increase bowel movement frequency; in active diarrheal states that effect is undesirable and may worsen electrolyte loss. <li>Scientific_Study_Title: An open-label, prospective clinical study to evaluate the efficacy and safety of TLPL/AY/01/2008 in the management of functional constipation (contains Triphala). <li>Scientific_Study_Authors: Munshi R., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22022157/ <li>Scientific_Study_Excerpt: <p>This clinical trial demonstrated that a formulation including Triphala increased weekly bowel movements and improved stool form in patients with functional constipation, supporting Triphala's laxative action in humans. The study authors reported improved transit and stool characteristics, indicating that Triphala can meaningfully accelerate bowel motility; by extension, in conditions of active diarrhea or fluid loss those same properties could be harmful rather than therapeutic.</p> </ul> <h4>Concurrent use with anticoagulants / bleeding disorders</h4> <ul> <li>🩸 <li>Recommendation: Avoid using Triphala with prescription blood thinners (e.g., warfarin) without close medical supervision and monitoring of coagulation (INR) or bleeding signs. <li>Reasoning: Triphala extracts inhibit several cytochrome P450 isoforms and contain compounds that may affect platelet function or alter drug metabolism, which can change levels of anticoagulant drugs and bleeding risk. <li>Scientific_Study_Title: Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. <li>Scientific_Study_Authors: Sornkanok S., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35785236/ <li>Scientific_Study_Excerpt: <p>Using human liver microsomes and rat pharmacokinetics, the authors showed Triphala inhibited CYP1A2, CYP3A4 and other isoforms in vitro and, when co-administered orally in rats, increased the bioavailabilities of phenacetin and midazolam by approximately 61% and 41% respectively. These findings provide direct experimental evidence that Triphala can alter drug metabolism and systemic exposure of CYP-substrate drugs, supporting caution when combined with narrow-therapeutic-index agents like warfarin.</p> </ul> <h4>Severe electrolyte imbalance / hypovolemia</h4> <ul> <li>⚠️ <li>Recommendation: Do not use Triphala as a cleansing/purgative regimen during states of severe electrolyte imbalance or ongoing vomiting/diarrhea; consult a clinician first. <li>Reasoning: Because Triphala can increase bowel movements and has mild purgative effects, it can worsen fluid and electrolyte losses in vulnerable patients. <li>Scientific_Study_Title: The Significance of Ayurvedic Medicinal Plants (review discussing classical cautions). <li>Scientific_Study_Authors: Srikanth N., et al. <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC5871155/ <li>Scientific_Study_Excerpt: <p>The review outlines traditional contraindications for various Ayurvedic plants and formulations, noting that laxative or purgative herbs (including Triphala) can produce symptoms such as diarrhea, dehydration and electrolyte disturbance when misused. The authors recommend avoiding such agents in patients with active fluid loss or severe systemic weakness unless managed by an experienced practitioner.</p> </ul> <h3> Relative Contraindications of Triphala </h3> <h4>Diabetes or concurrent antidiabetic medications</h4> <ul> <li>📉 <li>Recommendation: If you have diabetes and take glucose-lowering drugs, consult your clinician and monitor blood glucose closely if you start Triphala; dose adjustments of diabetes medications may be required. <li>Reasoning: Clinical studies and systematic reviews report Triphala can lower fasting blood glucose; when combined with antidiabetic drugs this may increase risk of hypoglycemia. <li>Scientific_Study_Title: Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. <li>Scientific_Study_Authors: Poonyachoti S., et al. <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8072855/ <li>Scientific_Study_Excerpt: <p>The review pooled randomized and controlled studies and found that Triphala supplementation was associated with reductions in fasting blood glucose in diabetic patients and improvements in lipid measures in some trials. The authors conclude that Triphala can affect metabolic parameters and recommend clinical monitoring when used with conventional antidiabetic therapy, because additive glucose-lowering effects were observed in patient groups studied.</p> </ul> <h4>Concomitant use with drugs metabolized by CYP3A4 / CYP1A2 / CYP2D6</h4> <ul> <li>💊 <li>Recommendation: Use caution and consult a clinician or pharmacist before combining Triphala with medications primarily cleared by CYP enzymes (e.g., some statins, benzodiazepines, certain antidepressants); monitoring or dose adjustment may be needed. <li>Reasoning: In vitro and in vivo studies show Triphala inhibits multiple CYP isoforms and can increase bioavailability of probe drugs, indicating potential clinically relevant herb-drug interactions. <li>Scientific_Study_Title: Cytochrome P450 inhibitory potential of Triphala--a Rasayana from Ayurveda. <li>Scientific_Study_Authors: Ganesan A., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/20883765/ <li>Scientific_Study_Excerpt: <p>The investigators measured Triphala and its components for CYP450 inhibition and reported measurable inhibition of rat liver microsomal CYP450 and of human CYP3A4 and CYP2D6 in fluorescence assays, with IC50s reported for individual isoforms. The study highlights the potential for Triphala to alter co-administered drug metabolism and underscores the need for interaction consideration when combining Triphala with drugs metabolized by these pathways.</p> </ul> <h4>Iron-deficiency anemia or concurrent iron supplementation</h4> <ul> <li>🩺 <li>Recommendation: Space Triphala and iron supplements by several hours or avoid simultaneous use; monitor iron indices if used chronically. <li>Reasoning: Some Triphala components (especially Terminalia spp.) show iron-chelating/tannin activity in vitro and in animal models, which could reduce iron bioavailability or interfere with iron supplementation. <li>Scientific_Study_Title: Reducing power and iron chelating property of Terminalia chebula alleviates iron induced liver toxicity in mice. <li>Scientific_Study_Authors: Pawar R., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22938047/ <li>Scientific_Study_Excerpt: <p>Terminalia chebula extract demonstrated in vitro iron-chelating activity and, in iron-overloaded mice, reduced indices of iron-induced oxidative injury. The authors report potent chelation and biochemical effects consistent with modulation of iron handling, suggesting that Terminalia extracts can affect iron chemistry and therefore could influence iron absorption or status when taken with iron supplements.</p> </ul>
Heading
<h4>Loose stools / diarrhea</h4> <ul> <li>💩 <li>Side effect summary: Triphala commonly produces a mild laxative effect; some users report loose stools or abdominal cramping, especially when starting or at higher doses. <li>Recommendation: Start with low dose, ensure adequate hydration, stop if diarrhea is severe or persistent and consult a clinician. <li>Reasoning: Clinical and experimental studies confirm Triphala increases bowel motility and stool frequency; this explains reported gastrointestinal looseness in susceptible people. <li>Severity Level: Mild <li>Scientific_Study_Available: Yes <li>Scientific_Study_Title: An open-label, prospective clinical study to evaluate the efficacy and safety of TLPL/AY/01/2008 in the management of functional constipation. <li>Scientific_Study_Authors: Munshi R., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22022157/ <li>Scientific_Study_Excerpt: <p>The trial that included Triphala as part of a laxative formula showed a clinically significant increase in weekly bowel movements and improved stool form in constipated patients, demonstrating Triphala’s pro-kinetic/laxative effects. Those same properties are the likely mechanism for loose stools when taken by people who are sensitive or who take higher-than-recommended doses.</p> </ul> <h4>Low blood sugar when combined with diabetes medications</h4> <ul> <li>🩹 <li>Side effect summary: Triphala can lower fasting glucose; when taken with insulin or sulfonylureas it can increase hypoglycemia risk. <li>Recommendation: Diabetics should monitor blood glucose more frequently when starting Triphala and discuss medication adjustments with their clinician. <li>Reasoning: Multiple trials and a systematic review show Triphala reduces fasting glucose and can lower post-prandial sugar in diabetics, implying additive effects with glucose-lowering drugs. <li>Severity Level: Moderate <li>Scientific_Study_Available: Yes <li>Scientific_Study_Title: Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. <li>Scientific_Study_Authors: Poonyachoti S., et al. <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8072855/ <li>Scientific_Study_Excerpt: <p>The systematic review pooled multiple human trials and found statistically significant reductions in fasting blood glucose among diabetic participants receiving Triphala. The authors conclude Triphala exerts hypoglycemic effects under some clinical conditions, supporting clinical monitoring when combined with antidiabetic therapies to avoid hypoglycemia.</p> </ul> <h4>Potential for herb-drug interactions (altered drug levels)</h4> <ul> <li>⚖️ <li>Side effect summary: Triphala can inhibit CYP enzymes and may increase or decrease levels of certain prescription drugs, leading to increased side effects or reduced efficacy. <li>Recommendation: If you take medications with narrow therapeutic ranges or those metabolized by CYP1A2/3A4/2D6, consult your clinician/pharmacist before starting Triphala. <li>Reasoning: In vitro and animal pharmacokinetic studies demonstrate CYP inhibition and increased bioavailability of probe drugs after Triphala co-administration. <li>Severity Level: Moderate <li>Scientific_Study_Available: Yes <li>Scientific_Study_Title: Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. <li>Scientific_Study_Authors: Sornkanok S., et al. <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35785236/ <li>Scientific_Study_Excerpt: <p>Human liver microsome assays and rat pharmacokinetic studies showed Triphala inhibited several CYP isoforms in vitro and increased the oral bioavailability of phenacetin (CYP1A2 probe) and midazolam (CYP3A4 probe) in rats by substantial margins. These results indicate a potential for clinically meaningful herb-drug interactions with drugs cleared by these enzymes.</p> </ul>
Heading
<h4>Anticoagulants (e.g., warfarin)</h4> <ul> <li>Interaction_Details: Triphala can affect drug-metabolizing enzymes and contains compounds that may influence platelet function; this may change blood thinner levels or bleeding tendency. <li>Severity: Severe <li>Recommendation: Avoid unsupervised use with warfarin or other anticoagulants; if combined, perform frequent INR or clotting monitoring and consult the prescriber. <li>Scientific_Study_Available: Yes <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35785236/ <li>Scientific_Study_Title: Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. <li>Scientfic_Study_Authors: Sornkanok S., et al. <li>Scientific_Study_Excerpt: <p>The study demonstrated reversible inhibition of CYP isoforms (notably CYP1A2 and CYP3A4) by Triphala in human liver microsomes and showed increased plasma exposure to phenacetin and midazolam in rats after co-administration. Given warfarin’s narrow therapeutic index and metabolism involving CYP enzymes, these pharmacokinetic interactions suggest a plausible mechanism by which Triphala could alter anticoagulant exposure and bleeding risk - therefore clinical caution and laboratory monitoring are advised.</p> </ul> <h4>Benzodiazepines and sedatives (CYP3A4 substrates, e.g., midazolam)</h4> <ul> <li>Interaction_Details: Triphala inhibited CYP3A4 in vitro and increased midazolam bioavailability in animal models, suggesting increased sedative exposure and stronger effects. <li>Severity: Moderate <li>Recommendation: Consult your clinician before combining; dose reduction or monitoring is advisable if co-use cannot be avoided. <li>Scientific_Study_Available: Yes <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35785236/ <li>Scientific_Study_Title: Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. <li>Scientfic_Study_Authors: Sornkanok S., et al. <li>Scientific_Study_Excerpt: <p>In rats, oral Triphala (500 mg/kg) increased midazolam systemic exposure by roughly 40%, consistent with in vitro CYP3A4 inhibition. The result demonstrates that co-administration can raise plasma concentrations of CYP3A4 substrates and potentially intensify or prolong their pharmacologic effects, which is clinically relevant for sedatives and other CYP3A4-metabolized drugs.</p> </ul> <h4>Drugs metabolized by CYP1A2 (e.g., theophylline, some antidepressants)</h4> <ul> <li>Interaction_Details: Triphala shows inhibitory activity against CYP1A2 in vitro and increased phenacetin bioavailability in rats, indicating potential elevation of drugs cleared by CYP1A2. <li>Severity: Moderate <li>Recommendation: Check with a clinician or pharmacist before starting Triphala if you take CYP1A2 substrates; monitoring for increased effects or toxicity is advised. <li>Scientific_Study_Available: Yes <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35785236/ <li>Scientific_Study_Title: Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. <li>Scientfic_Study_Authors: Sornkanok S., et al. <li>Scientific_Study_Excerpt: <p>The research measured Triphala’s IC50 values against several CYP isoforms and observed increased phenacetin exposure in rats, supporting the conclusion that Triphala can slow metabolism of CYP1A2 substrates. This suggests that drugs primarily cleared by CYP1A2 could accumulate to higher levels when taken with Triphala, warranting caution and possible dose adjustment.</p> </ul> <h4>Antidiabetic agents (insulin, sulfonylureas, metformin)</h4> <ul> <li>Interaction_Details: Clinical studies show Triphala lowers fasting glucose; co-administration with glucose-lowering drugs can increase hypoglycemia risk. <li>Severity: Moderate <li>Recommendation: Monitor blood glucose closely and consult your diabetes care team; medication dose changes may be needed. <li>Scientific_Study_Available: Yes <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8072855/ <li>Scientific_Study_Title: Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. <li>Scientfic_Study_Authors: Poonyachoti S., et al. <li>Scientific_Study_Excerpt: <p>The systematic review compiled randomized trials showing triphala-associated reductions in fasting glucose in diabetic patients. The authors advise clinical monitoring because combining Triphala with conventional antidiabetic medications could produce additive glucose-lowering effects and increase risk of symptomatic or severe hypoglycemia in susceptible patients.</p> </ul> <h4>Oral iron supplements / iron therapy</h4> <ul> <li>Interaction_Details: Terminalia constituents demonstrate iron-chelating activity in vitro and in animal models, potentially lowering iron absorption or altering iron status when taken concurrently with oral iron. <li>Severity: Mild <li>Recommendation: Separate Triphala and iron supplements by at least 2-3 hours; monitor hemoglobin/iron indices if used long-term together. <li>Scientific_Study_Available: Yes <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22938047/ <li>Scientific_Study_Title: Reducing power and iron chelating property of Terminalia chebula (Retz.) alleviates iron induced liver toxicity in mice. <li>Scientfic_Study_Authors: Pulla Reddy AC., Lokesh BR. <li>Scientific_Study_Excerpt: <p>The authors demonstrated Terminalia chebula’s in vitro iron-chelating capability and showed modulation of iron-related toxic effects in iron-overloaded mice. These properties indicate Terminalia extracts can interact with iron chemistry in the gut or systemically, implying that concurrent oral iron supplementation might be affected; therefore, temporal separation or monitoring is a practical precaution.</p> </ul>
